NCT00792467 2021-05-11
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma
Italfarmaco
Phase 1/2 Completed
Italfarmaco
Celgene
Ohio State University Comprehensive Cancer Center
Chong Kun Dang Pharmaceutical
H. Lee Moffitt Cancer Center and Research Institute